⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMT News
Sagimet Biosciences Inc. Series A Common Stock
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
globenewswire.com
SGMT
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
globenewswire.com
SGMT
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
globenewswire.com
SGMT
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
globenewswire.com
SGMT
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
SGMT
Form 8-K
sec.gov
SGMT
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
globenewswire.com
SGMT
Form 8-K
sec.gov
SGMT
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com
SGMT
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
globenewswire.com
SGMT